Sensus Healthcare (SRTS) Competitors

$3.19 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$3.20 +0.00 (+0.16%)

As of 05/22/2026 04:10 PM Eastern

SRTS vs. SMTI, TLSI, STEX, LUCD, and INFU

Should you buy Sensus Healthcare stock or one of its competitors? MarketBeat compares Sensus Healthcare with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sensus Healthcare include Sanara MedTech (SMTI), TriSalus Life Sciences (TLSI), Biosig Technologies (STEX), Lucid Diagnostics (LUCD), and InfuSystem (INFU). These companies are all part of the "medical equipment" industry.

How does Sensus Healthcare compare to Sanara MedTech?

Sanara MedTech (NASDAQ:SMTI) and Sensus Healthcare (NASDAQ:SRTS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

In the previous week, Sanara MedTech and Sanara MedTech both had 3 articles in the media. Sanara MedTech's average media sentiment score of 0.00 beat Sensus Healthcare's score of -0.08 indicating that Sanara MedTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanara MedTech	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sensus Healthcare	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sanara MedTech has a net margin of -31.23% compared to Sensus Healthcare's net margin of -34.50%. Sanara MedTech's return on equity of -3.19% beat Sensus Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-31.23%	-3.19%	-0.56%
Sensus Healthcare	-34.50%	-15.79%	-14.02%

Sensus Healthcare has lower revenue, but higher earnings than Sanara MedTech. Sensus Healthcare is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$103.12M	2.06	-$37.56M	-$3.77	N/A
Sensus Healthcare	$27.48M	1.91	-$7.72M	-$0.47	N/A

8.1% of Sanara MedTech shares are owned by institutional investors. Comparatively, 25.3% of Sensus Healthcare shares are owned by institutional investors. 42.0% of Sanara MedTech shares are owned by insiders. Comparatively, 10.2% of Sensus Healthcare shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Sanara MedTech currently has a consensus price target of $34.00, suggesting a potential upside of 46.74%. Sensus Healthcare has a consensus price target of $6.88, suggesting a potential upside of 115.52%. Given Sensus Healthcare's stronger consensus rating and higher probable upside, analysts clearly believe Sensus Healthcare is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sensus Healthcare	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Sanara MedTech has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market. Comparatively, Sensus Healthcare has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market.

Summary

Sanara MedTech beats Sensus Healthcare on 8 of the 15 factors compared between the two stocks.

How does Sensus Healthcare compare to TriSalus Life Sciences?

TriSalus Life Sciences (NASDAQ:TLSI) and Sensus Healthcare (NASDAQ:SRTS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

TriSalus Life Sciences presently has a consensus price target of $7.50, suggesting a potential upside of 130.06%. Sensus Healthcare has a consensus price target of $6.88, suggesting a potential upside of 115.52%. Given TriSalus Life Sciences' higher possible upside, equities analysts clearly believe TriSalus Life Sciences is more favorable than Sensus Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Sensus Healthcare	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Sensus Healthcare has a net margin of -34.50% compared to TriSalus Life Sciences' net margin of -60.85%. TriSalus Life Sciences' return on equity of 0.00% beat Sensus Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-60.85%	N/A	-69.91%
Sensus Healthcare	-34.50%	-15.79%	-14.02%

In the previous week, TriSalus Life Sciences had 10 more articles in the media than Sensus Healthcare. MarketBeat recorded 13 mentions for TriSalus Life Sciences and 3 mentions for Sensus Healthcare. TriSalus Life Sciences' average media sentiment score of 0.53 beat Sensus Healthcare's score of -0.08 indicating that TriSalus Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TriSalus Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
Sensus Healthcare	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

TriSalus Life Sciences has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, Sensus Healthcare has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market.

Sensus Healthcare has lower revenue, but higher earnings than TriSalus Life Sciences. Sensus Healthcare is trading at a lower price-to-earnings ratio than TriSalus Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$44.88M	4.45	-$39.23M	-$1.41	N/A
Sensus Healthcare	$27.48M	1.91	-$7.72M	-$0.47	N/A

2.6% of TriSalus Life Sciences shares are held by institutional investors. Comparatively, 25.3% of Sensus Healthcare shares are held by institutional investors. 16.3% of TriSalus Life Sciences shares are held by insiders. Comparatively, 10.2% of Sensus Healthcare shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

TriSalus Life Sciences and Sensus Healthcare tied by winning 8 of the 16 factors compared between the two stocks.

How does Sensus Healthcare compare to Biosig Technologies?

Biosig Technologies (NASDAQ:STEX) and Sensus Healthcare (NASDAQ:SRTS) are both small-cap medical equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

Biosig Technologies has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market. Comparatively, Sensus Healthcare has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market.

Biosig Technologies has a net margin of 0.00% compared to Sensus Healthcare's net margin of -34.50%. Sensus Healthcare's return on equity of -15.79% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	-717.92%	-336.75%
Sensus Healthcare	-34.50%	-15.79%	-14.02%

In the previous week, Biosig Technologies had 2 more articles in the media than Sensus Healthcare. MarketBeat recorded 5 mentions for Biosig Technologies and 3 mentions for Sensus Healthcare. Biosig Technologies' average media sentiment score of 0.49 beat Sensus Healthcare's score of -0.08 indicating that Biosig Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biosig Technologies	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sensus Healthcare	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

7.2% of Biosig Technologies shares are owned by institutional investors. Comparatively, 25.3% of Sensus Healthcare shares are owned by institutional investors. 52.7% of Biosig Technologies shares are owned by company insiders. Comparatively, 10.2% of Sensus Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Sensus Healthcare has higher revenue and earnings than Biosig Technologies. Sensus Healthcare is trading at a lower price-to-earnings ratio than Biosig Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	N/A	N/A	-$462.77M	-$9.71	N/A
Sensus Healthcare	$27.48M	1.91	-$7.72M	-$0.47	N/A

Biosig Technologies presently has a consensus target price of $8.00, indicating a potential upside of 525.00%. Sensus Healthcare has a consensus target price of $6.88, indicating a potential upside of 115.52%. Given Biosig Technologies' higher possible upside, equities research analysts plainly believe Biosig Technologies is more favorable than Sensus Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sensus Healthcare	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Sensus Healthcare beats Biosig Technologies on 8 of the 15 factors compared between the two stocks.

How does Sensus Healthcare compare to Lucid Diagnostics?

Sensus Healthcare (NASDAQ:SRTS) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Sensus Healthcare currently has a consensus price target of $6.88, indicating a potential upside of 115.52%. Lucid Diagnostics has a consensus price target of $4.13, indicating a potential upside of 285.51%. Given Lucid Diagnostics' stronger consensus rating and higher probable upside, analysts clearly believe Lucid Diagnostics is more favorable than Sensus Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensus Healthcare	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

25.3% of Sensus Healthcare shares are owned by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are owned by institutional investors. 10.2% of Sensus Healthcare shares are owned by insiders. Comparatively, 6.8% of Lucid Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Sensus Healthcare has higher revenue and earnings than Lucid Diagnostics. Sensus Healthcare is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensus Healthcare	$27.48M	1.91	-$7.72M	-$0.47	N/A
Lucid Diagnostics	$5.13M	42.32	-$58.01M	-$0.47	N/A

Sensus Healthcare has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market. Comparatively, Lucid Diagnostics has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market.

In the previous week, Sensus Healthcare had 1 more articles in the media than Lucid Diagnostics. MarketBeat recorded 3 mentions for Sensus Healthcare and 2 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 1.96 beat Sensus Healthcare's score of -0.08 indicating that Lucid Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sensus Healthcare	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lucid Diagnostics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Sensus Healthcare has a net margin of -34.50% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat Sensus Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensus Healthcare	-34.50%	-15.79%	-14.02%
Lucid Diagnostics	-876.72%	N/A	-116.26%

Summary

Sensus Healthcare beats Lucid Diagnostics on 8 of the 15 factors compared between the two stocks.

How does Sensus Healthcare compare to InfuSystem?

Sensus Healthcare (NASDAQ:SRTS) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

InfuSystem has a net margin of 1.12% compared to Sensus Healthcare's net margin of -34.50%. InfuSystem's return on equity of 2.78% beat Sensus Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensus Healthcare	-34.50%	-15.79%	-14.02%
InfuSystem	1.12%	2.78%	1.41%

InfuSystem has higher revenue and earnings than Sensus Healthcare. Sensus Healthcare is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensus Healthcare	$27.48M	1.91	-$7.72M	-$0.47	N/A
InfuSystem	$142.40M	1.37	$870K	$0.38	25.42

25.3% of Sensus Healthcare shares are held by institutional investors. Comparatively, 71.1% of InfuSystem shares are held by institutional investors. 10.2% of Sensus Healthcare shares are held by insiders. Comparatively, 10.8% of InfuSystem shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Sensus Healthcare presently has a consensus target price of $6.88, suggesting a potential upside of 115.52%. InfuSystem has a consensus target price of $15.00, suggesting a potential upside of 55.28%. Given Sensus Healthcare's higher probable upside, analysts plainly believe Sensus Healthcare is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensus Healthcare	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Sensus Healthcare has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market. Comparatively, InfuSystem has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market.

In the previous week, Sensus Healthcare and Sensus Healthcare both had 3 articles in the media. InfuSystem's average media sentiment score of 0.93 beat Sensus Healthcare's score of -0.08 indicating that InfuSystem is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sensus Healthcare	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
InfuSystem	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

InfuSystem beats Sensus Healthcare on 12 of the 15 factors compared between the two stocks.

Get Sensus Healthcare News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SRTS vs. The Competition

Export

Metric	Sensus Healthcare	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$52.51M	$6.97B	$6.43B	$12.32B
Dividend Yield	N/A	1.68%	2.76%	5.28%
P/E Ratio	-6.79	47.45	21.00	25.66
Price / Sales	1.91	84.61	615.84	111.99
Price / Cash	N/A	24.91	43.49	56.67
Price / Book	1.15	6.53	10.37	7.14
Net Income	-$7.72M	$158.81M	$3.57B	$335.98M
7 Day Performance	-8.07%	3.72%	6.00%	3.56%
1 Month Performance	-19.04%	0.74%	3.51%	2.54%
1 Year Performance	-31.98%	3.17%	34.12%	35.05%

Sensus Healthcare Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SRTS Sensus Healthcare	3.3173 of 5 stars	$3.19 flat	$6.88 +115.5%	-32.0%	$52.51M	$27.48M	N/A	40
SMTI Sanara MedTech	2.1537 of 5 stars	$21.79 -0.5%	$34.00 +56.1%	-23.8%	$202.39M	$103.12M	N/A	60
TLSI TriSalus Life Sciences	3.3673 of 5 stars	$3.28 +8.4%	$7.50 +128.4%	-41.4%	$201.15M	$44.88M	N/A	106	Gap Up
STEX Biosig Technologies	2.3264 of 5 stars	$1.08 +9.2%	$9.00 +732.6%	N/A	$196.90M	N/A	N/A	50
LUCD Lucid Diagnostics	4.3707 of 5 stars	$0.96 +0.5%	$4.13 +329.7%	-32.7%	$195.35M	$5.13M	N/A	70	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SRTS) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sensus Healthcare (SRTS) Competitors

SRTS vs. SMTI, TLSI, STEX, LUCD, and INFU

How does Sensus Healthcare compare to Sanara MedTech?

Summary

How does Sensus Healthcare compare to TriSalus Life Sciences?

Summary

How does Sensus Healthcare compare to Biosig Technologies?

Summary

How does Sensus Healthcare compare to Lucid Diagnostics?

Summary

How does Sensus Healthcare compare to InfuSystem?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRTS vs. The Competition

Sensus Healthcare Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sensus Healthcare (SRTS) Competitors

SRTS vs. SMTI, TLSI, STEX, LUCD, and INFU

How does Sensus Healthcare compare to Sanara MedTech?

Does the media refer more to SMTI or SRTS?

Is SMTI or SRTS more profitable?

Which has higher earnings & valuation, SMTI or SRTS?

Do insiders & institutionals hold more shares of SMTI or SRTS?

Do analysts rate SMTI or SRTS?

Which has more risk & volatility, SMTI or SRTS?

Summary

How does Sensus Healthcare compare to TriSalus Life Sciences?

Do analysts recommend TLSI or SRTS?

Is TLSI or SRTS more profitable?

Does the media prefer TLSI or SRTS?

Which has more volatility & risk, TLSI or SRTS?

Which has better valuation & earnings, TLSI or SRTS?

Do institutionals & insiders hold more shares of TLSI or SRTS?

Summary

How does Sensus Healthcare compare to Biosig Technologies?

Which has more risk and volatility, STEX or SRTS?

Is STEX or SRTS more profitable?

Does the media refer more to STEX or SRTS?

Do institutionals & insiders believe in STEX or SRTS?

Which has stronger valuation & earnings, STEX or SRTS?

Do analysts recommend STEX or SRTS?

Summary

How does Sensus Healthcare compare to Lucid Diagnostics?

Do analysts recommend SRTS or LUCD?

Do institutionals & insiders believe in SRTS or LUCD?

Which has stronger earnings & valuation, SRTS or LUCD?

Which has more volatility and risk, SRTS or LUCD?

Does the media prefer SRTS or LUCD?

Is SRTS or LUCD more profitable?

Summary

How does Sensus Healthcare compare to InfuSystem?

Is SRTS or INFU more profitable?

Which has stronger valuation and earnings, SRTS or INFU?

Do institutionals and insiders have more ownership in SRTS or INFU?

Do analysts prefer SRTS or INFU?

Which has more volatility and risk, SRTS or INFU?

Does the media favor SRTS or INFU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRTS vs. The Competition

Sensus Healthcare Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools